Management of Pruritus in the Elderly

Initial Management and First-Line Oral Medication

The British Journal of Dermatology recommends emollients with high lipid content and topical steroids for at least 2 weeks to exclude asteatotic eczema, the most common cause of elderly pruritus, before initiating oral therapy 1, 2, 3
Gabapentin is the preferred oral agent specifically for elderly pruritus, with a Strength D recommendation for pruritus in elderly skin 1, 2
The British Journal of Dermatology recommends gabapentin as the first-line oral medication for elderly patients with pruritus, while sedative antihistamines should be avoided due to safety concerns 1, 2

The British Journal of Dermatology recommends fexofenadine 180 mg or loratadine 10 mg orally as second-line options for generalized pruritus of unknown origin 1, 4, 3
Mildly sedative cetirizine 10 mg may be used if non-sedating options fail, according to the British Journal of Dermatology 1, 4
The British Journal of Dermatology suggests combining H1 and H2 antagonists (e.g., fexofenadine with cimetidine) for enhanced effect 1, 4
Alternative systemic agents, including paroxetine or fluvoxamine (SSRIs), mirtazapine, pregabalin, naltrexone, and ondansetron or aprepitant, may be considered for refractory cases, all with Strength D recommendations, as per the British Journal of Dermatology 1, 4

The British Journal of Dermatology explicitly contraindicates sedative antihistamines (e.g., hydroxyzine) in elderly patients with pruritus, due to fall risk, cognitive impairment, and anticholinergic burden, with a Strength of recommendation C 1, 2, 3

The British Journal of Dermatology recommends against starting oral medications without adequate topical therapy trial (minimum 2 weeks) and using sedative antihistamines due to familiarity, despite clear evidence against their use in the elderly 1, 2
Referral to secondary care is recommended if diagnostic uncertainty exists or primary care management (topical therapy plus gabapentin) fails to relieve symptoms, according to the British Journal of Dermatology and Praxis Medical Insights 1, 2, 3